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Abstract: The identification of extracellular phospholipid vesicles as conveyors of cellular 
information has created excitement in the field of drug delivery. Biological therapeutics, including 
short interfering RNA and recombinant proteins, are prone to degradation, have limited ability 
to cross biological membranes, and may elicit immune responses. Therefore, delivery systems 
for such drugs are under intensive investigation. Exploiting extracellular vesicles as carriers for 
biological therapeutics is a promising strategy to overcome these issues and to achieve efficient 
delivery to the cytosol of target cells. Exosomes are a well studied class of extracellular vesicles 
known to carry proteins and nucleic acids, making them especially suitable for such strategies. 
However, the considerable complexity and the related high chance of off-target effects of these 
carriers are major barriers for translation to the clinic. Given that it is well possible that not 
all components of exosomes are required for their proper functioning, an alternative strategy 
would be to mimic these vesicles synthetically. By assembly of liposomes harboring only 
crucial components of natural exosomes, functional exosome mimetics may be created. The 
low complexity and use of well characterized components strongly increase the pharmaceutical 
acceptability of such systems. However, exosomal components that would be required for the 
assembly of functional exosome mimetics remain to be identified. This review provides insights 
into the composition and functional properties of exosomes, and focuses on components which 
could be used to enhance the drug delivery properties of exosome mimetics.
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Introduction
Cells are well known to communicate via soluble mediators or cell-cell contact, but 
in recent decades, intercellular communication through extracellular vesicles has 
also increasingly gained attention. The first notion of such vesicles arose when Wolf 
described the formation of “platelet dust” upon storage of blood platelets.1 These 
phospholipid-rich particles were shown to exert coagulant activity and were later 
determined to be actively shed membrane-derived vesicles.2 Since then our knowledge 
about such vesicles has expanded dramatically, and vesicle secretion is now widely 
accepted to occur in most, if not all, cell types. Characterization studies identified 
three main populations of extracellular vesicles, which are commonly classified based 
on their intracellular origin. Cells that undergo apoptosis fractionate their cellular 
content into subcellular apoptotic bodies in order to prevent leakage of possibly toxic 
or immunogenic cellular contents into the extracellular matrix (Figure 1, left panel).3 
Apoptotic bodies appear as a heterogeneous group of vesicles, with sizes ranging from 
50 nm to 5 µm and a buoyant density of 1.16–1.28 g/mL.4–7 They contain a variety 
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of cellular contents, including DNA, RNA, and histones, 
and display “eat-me” signaling molecules, causing them to 
be rapidly cleared by macrophages.8,9 Due to their specific 
cellular content and high density, they may be distinguished 
from two other major vesicle populations, which show con-
siderably more overlap.
One of these populations originates from budding and 
fission from the plasma membrane into the extracellular 
space (Figure 1, middle panel) and contains vesicles of 
about 50–1000 nm in size. Such vesicles are interchange-
ably referred to as microvesicles,10 ectosomes,11 shedding 
vesicles,12 microparticles,13,14 plasma membrane-derived 
vesicles,15 or even exovesicles.16 In order to avoid confu-
sion and promote standardization of nomenclature, the term 
“microvesicles” will be used in this review to denote this 
vesicle population. The buoyant density of microvesicles is 
still not well defined7 and also the intracellular mechanisms 
for vesicle release remain unclear. Microvesicle secretion 
may take place in resting cells, but the vesicle shedding 
rate increases dramatically upon stimulation. The stimuli 
and intensity of stimuli required for vesicle formation can 
vary among cell types. As a common principle, increasing 
intracellular levels of Ca2+ result in increased secretion of 
microvesicles.17,18 For example, erythrocytes can be stimu-
lated with high levels of extracellular Ca2+ in combination 
with a suitable ionophore.19,20 In various human tumor cell 
lines, microvesicle production was increased at extracellular 
Ca2+ concentrations up to 25 mM, but concentrations higher 
than 10 mM also decreased cell viability.21 Other common 
stimulators for microvesicle release include lipopolysaccha-
ride for monocytes,22 and activation of the P2X7 receptor with 
ATP for macrophages and other myeloid cells.23,24
The last population of secreted membrane vesicles com-
prises exosomes, which differ from microvesicles mainly in 
their intracellular origin. Whereas microvesicles are supposedly 
generated by budding from the plasma membrane, exosomes 
appear to be formed by tightly controlled inward budding 
into large multivesicular bodies in the cytosol. These multi-
vesicular bodies are able to fuse with the plasma membrane, 
causing the release of exosomes into the extracellular space 
(Figure 1, right panel).25 In theory, exosomes and microvesicles 
are clearly distinguishable by their origin, but in practice 
such a distinction is seldom possible. Therefore, attempts are 
made to characterize and separate both populations based on 
phenotypical features, such as buoyant density, size, morphol-
ogy, and protein and lipid composition. Exosomes typically 
share characteristics with the vesicles inside multivesicular 
bodies. They are commonly 40–100 nm in size,26 although 
somewhat larger diameters have been reported.27 When 
analyzed by electron microscopy, exosomes show a typical cup-
shaped morphology,28 but in biological fluids they are likely 
to exist as spherical structures.29 In addition to being more 
homogenous in size than microvesicles, they are thought to be 
more dense and float on a sucrose density   gradient at heights 
Figure 1 Schematic presentation of the biogenesis and composition of the three main classes of extracellular vesicles. Apoptotic bodies (left panel) are formed when cells 
enter apoptosis, and may contain nuclear material such as histones and DNA. They are heterogenous in size (50–5000 nm), irregularly shaped and harbor a variety of cellular 
proteins. Microvesicles (middle panel) are formed by budding and subsequent fission of the plasma membrane. Selective incorporation of membrane proteins and cytosolic 
proteins takes place during formation, resulting in vesicles which may be enriched in specific proteins and lipids compared to the parent cell. Microvesicles are thought to be 
smaller than apoptotic bodies (50–1000 nm) and more homogenously shaped. Selective enrichment of cellular content also occurs during the formation of exosomes (right 
panel), however exosomes originate from budding into the limiting membrane of large endosomal structures named multivesicular bodies (denoted with MVB). This process 
is facilitated by endosomal proteins. Subsequent fusion of MVBs with the plasma membrane results in release of the exosomes. Exosomes are small (,100 nm), relatively 
homogenous in size, and may contain (endosomal) proteins involved in their assembly, such as CD9, Alix and TSG101. 
Abbreviation: NC, nucleus. 
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of 1.13–1.19 g/mL.26 Furthermore,   exosomes often contain 
specific proteins which are incorporated during the formation 
process in multivesicular bodies, such as Alix, TSG101, and 
tetraspanins (CD9, CD63),7,30 which are frequently used as 
markers for their identification.
Exosomes and microvesicles are involved in a large 
variety of body processes. They are concentrated carriers of 
genetic and proteomic information, and thus are believed to 
play important roles in intercellular communication. Secreted 
vesicles can transfer their messages in different ways. Firstly, 
they may activate target cells via ligands expressed on their 
surface. For example, it has been demonstrated that antigen-
presenting exosomes derived from dendritic cells provoke 
T cell-mediated immune responses in vivo.31 In addition to 
eliciting immune responses, ligand-receptor signaling via 
exosomes can also play a role in other regulatory processes, 
such as angiogenesis,32 hemostasis,33 and cancer progres-
sion.34 Secondly, secreted vesicles may transfer surface 
receptors from one cell to another by budding and subsequent 
fusion with plasma membranes of target cells.35,36 This mech-
anism may be exploited by the human immunodeficiency 
virus, increasing susceptibility to infection by transferring 
CD4 receptors from infected cells to noninfected cells.37 
  Additionally, the shedding of microvesicles has been pro-
posed to be a mechanism by which cells protect themselves 
from potentially harmful substances.12 A third mechanism 
of action is based on the horizontal transfer of proteins and 
genetic material, such as micro RNAs (miRNA), between 
cells. The cytosolic content of a donor cell can be transferred 
directly to the recipient cell following fusion or internaliza-
tion of microvesicles and exosomes.38,39 This results in the 
release of cargo into the cytosol of the target cell and subse-
quent intracellular signaling. An example of protein transfer 
between cells has recently been presented by Sarkar et al, 
who elegantly demonstrated that the intracellular apoptotic 
protein caspase-1 was transferred between monocytes and 
vascular smooth muscle cells via microvesicles, inducing 
apoptosis in the latter.40 The encapsulation of caspase-1 in 
microvesicles was shown to be necessary for the apoptotic 
effect of the enzyme.
First evidence of exosome-mediated transfer of mRNAs 
and miRNAs was recently presented by Valadi et al, who 
showed that exosomes from mouse mast cells contained 
substantial amounts of RNA.41 Many of the miRNAs were 
enriched compared with the parent cells, indicative of a 
selective incorporation process. Furthermore, mouse exo-
somes containing mRNA could be taken up by human mast 
cells, which resulted in the expression of mouse proteins 
in these cells. Additional evidence of functional miRNA 
transfer by exosomes was provided by Montecalvo et al, 
who showed that exosomes released from dendritic cells 
contained a variety of miRNAs.42 These exosomes were taken 
up by acceptor dendritic cells and effectively repressed target 
mRNA expression. Thus, while it has been suggested that 
only a minority of all circulating miRNA is confined within 
exosomes,43,44 exosomal miRNA may potently regulate gene 
expression in target cells in vivo. In addition to mRNA and 
miRNA, mitochondrial DNA (mtDNA) has been found 
in exosomes of astrocytes, myoblasts, and glioblastoma 
cells.45,46 Given that horizontal transfer of RNA by exosomes 
or microvesicles is important for cellular communication, 
vesicle-associated RNA may also serve as a diagnostic tool 
in disease. Disease states may cause specific miRNAs to be 
enriched in extracellular vesicles compared with healthy 
controls. For example, extracellular vesicles from patients 
with prostate cancer were selectively enriched in miR-141 
compared with healthy controls,47 and EGFRvIII mRNA 
in circulating microvesicles was associated with clinically 
distinct subtypes of glioblastoma.48 Viral infections may also 
be detected by analysis of exosomal RNA content.49
Exosomes and microvesicles are naturally adapted for the 
transport and intracellular delivery of proteins and nucleic 
acids. This makes them particularly attractive for the delivery 
of pharmaceutical proteins and nucleic acids, such as short 
interfering RNA (siRNA). Intracellular delivery of siRNA is a 
challenging task, given that naked siRNAs are rapidly degraded 
in the circulation, their large size and negative charge limits 
membrane passage and cellular uptake, some siRNA sequence 
motifs may elicit undesired immune responses, and targeting to 
specific tissues and cells is required to reduce adverse effects 
caused by off-target silencing.50,51   Encapsulation of nucleic 
acid-based therapeutics in endogenous transporting vesicles is 
a promising novel strategy to overcome most of these delivery 
issues. Exosomes may be most suitable for such strategies, 
because they are small (40–100 nm), relatively homogenous 
in size, and well studied. Their size ,100 nm is advantageous 
for their use as drug delivery systems, because this allows them 
to evade rapid clearance by the mononuclear phagocyte system 
and enhances passage through fenestrations in the vessel wall, 
as might occur during inflammation.52
Exosome-based drug delivery 
systems: biotechnological versus 
synthetic approaches
The successful use of exosomes for the targeted deliv-
ery  of  siRNA  has  been  recently  demonstrated  by 
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  Alvarez-Erviti et al.53 They harvested dendritic cells from 
mice and   transfected them to express the neuronal targeting 
ligand, RVG, coupled to the exosomal membrane protein, 
Lamp2b. This protein was expressed by the cells and incor-
porated in secreted exosomes. The exosomes were harvested, 
purified, and loaded with siRNA against an important protein 
in Alzheimer pathogenesis (BACE1) by electroporation. 
When the modified exosomes were injected intravenously 
in wild-type mice, a 60% decrease of BACE1 mRNA in 
the brain cortex was observed after 3 days. This ultimately 
resulted in a decrease (55%) of the harmful β-amyloid 
1–42 protein in the brain. Moreover, no increase in serum 
interleukin-6, interferon gamma-induced protein 10, tumor 
necrosis factor alpha and interferon alpha concentrations was 
observed after injection of the exosomes, suggesting that the 
modified exosomes were immunologically inert. However, 
immunological responses to repeated administration of exo-
somes were not evaluated, albeit repeated administration of 
exosomes loaded with siRNA against GAPDH did not result 
in a loss of silencing efficiency.
The biotechnological approach to create exosome-based 
delivery systems used by Alvarez-Erviti et al was the first 
demonstration of an exosome-based drug delivery system 
which showed efficient in vivo delivery of siRNA.53 Other 
strategies to exploit exosomes for therapeutic purposes 
have also been reported. In 2005, Delcayre et al described 
an “exosome display technology” in which various antigens 
were fused to the C1C2 domain of lactadherin.54 This pro-
tein domain binds to the lipid phosphatidylserine exposed 
by exosomes,55 resulting in the presentation of the fused 
antigen to the immune system. When Chinese hamster ovary 
cells were transfected with fusion constructs of C1C2 and 
interleukin-2 or granulocyte/monocyte colony-stimulating 
factor, the exosomes derived from these cells were signifi-
cantly enriched with the recombinant cytokines compared 
with the parent cells. Moreover, the recombinant exosomes 
were able to induce proliferative responses in interleukin-2 
and granulocyte/monocyte colony-stimulating factor-
dependent cell lines, respectively.54 The therapeutic potential 
of C1C2-coupled antigen display by exosomes was further 
explored in subsequent studies. These showed that tumors 
secreting exosome-bound ovalbumin grew slower than 
tumors secreting soluble ovalbumin, due to an enhanced 
immune stimulatory effect of the former.56 Furthermore, the 
tumor-associated antigens, carcinoembryonic antigen and 
HER2, elicited potent antitumor immune responses when 
recombinantly coupled with exosomes.57 The antitumor 
potential of this approach was also demonstrated in two 
prostate cancer models, in which tumor growth was severely 
attenuated by vaccination with exosomes displaying the 
tumor antigens, prostate-specific antigen or prostatic acid 
phosphatase.58 The feasibility of antitumor therapy based 
on immunostimulatory exosomes was evaluated in two 
Phase I trials.59,60 In these trials, dendritic cells of patients 
with stage III/IV melanoma were isolated and pulsed with 
MAGE3 tumor antigens.   Exosomes presenting MAGE3 were 
isolated and readministered to melanoma patients. Therapy 
appeared to be well tolerated by all patients and induced the 
desired immune effects in some patients, showing clinical 
feasibility for exosome-based therapeutics.
In addition to C1C2 coupling, therapeutics may also be 
nonspecifically bound to exosomes. This was recently dem-
onstrated by Sun et al, who showed that mixing curcumin 
with exosomes enhanced its bioavailability, stability, and 
solubility, and improved its anti-inflammatory activity in 
an in vivo lipopolysaccharide-induced septic shock model 
compared with curcumin alone.61 Furthermore, intranasally 
administered mouse lymphoma exosomes facilitated cur-
cumin and stat3 inhibitor delivery to brain microglia, induc-
ing anti-inflammatory and antitumor effects, respectively.62
The examples mentioned above all use endogenous exo-
somes in their full complexity (or with only minimal modifi-
cations to their natural content) to deliver therapeutic cargo. 
This may offer a range of advantages over conventional 
drug delivery systems, such as viral or synthetic (nonviral) 
nanoparticles. Virus-based drug delivery systems have some 
of the advantages of natural viruses, including their excellent 
capacity to invade host cells and incorporate their viral load 
into the host genome.63 However, their potential for inser-
tional mutagenesis or oncogenesis, high production costs, 
and risk of immunogenicity limit their clinical use.64 Nonviral 
drug delivery vehicles, such as cationic polyplexes and lipo-
plexes, are generally considered to be less immunogenic and 
mutagenic, but cytotoxicity and low transfection efficiencies 
in vivo are still major challenges to overcome.64,65
Exosome-based drug delivery systems may provide 
unique advantages over other systems, including limited or 
no undesired immunogenicity when self-derived exosomes 
are used, greater stability in the blood due to evasion of 
complement and coagulation factors,66 efficient delivery of 
cargo into the cytosol of the target cell, and possibly fewer 
off-target effects due to the natural tendency of exosomes to 
act on specific target cells.
Despite these advantages, there are still some major 
obstacles and challenges to overcome before endogenous 
exosomes may be used in a clinical setting. Naturally derived 
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exosomes are complex structures which are difficult to 
characterize pharmaceutically. In addition, they have com-
plicated roles in health and disease, which are still poorly 
understood.27,67,68 Therefore, they may induce adverse effects 
when used in pharmaceutical preparations. Thorough char-
acterization of exosome content and function is required to 
avoid such issues. Furthermore, biological fluids contain a 
mixture of extracellular vesicle populations from various cell 
types. The purification of single populations of cell-specific 
vesicles (eg, cancer cell-derived exosomes) still provides a 
barrier which hinders translation to the clinic. Highly purified 
populations of exosomes may be obtained from exosome-
secreting cell lines, but such exosomes may lack “self” 
signals and elicit undesired immune responses. In addition, 
nanotechnological approaches for scalable production and 
efficient loading of exosomes are lacking, and remain an 
area of investigation.69
A viable alternative for biotechnologically tailored 
exosome-based drug delivery systems is synthetic exosome 
mimetics. It is well possible that not all components in natural 
exosomes are required for specific and efficient delivery of 
cargo to the target cell. By extensive characterization of the 
lipid, protein, and nucleic acid content of exosomes, only 
functional components could be used for selective incorpo-
ration in exosome mimetics. Given that natural exosomes 
exist as spherical lipid bilayer structures, liposomes would 
provide a logical basis for the generation of exosome mimet-
ics. Similar to exosomes, liposomes are bilayered phospho-
lipid structures with (adjustable) diameters around 100 nm, 
which can be loaded with a variety of proteins, nucleic 
acids, or drug molecules.70,71 Liposomes have been shown to 
be valuable tools in drug delivery; several liposome-based 
drug delivery systems are currently in preclinical develop-
ment and clinical trials, while others have been approved for 
clinical development.71 The tailoring of liposomes to mimic 
exosomes could therefore provide a springboard for a novel 
class of nonviral drug delivery   systems. Such drug delivery 
systems would have the benefits of endogenous exosomes (eg, 
limited immunogenicity, efficient cargo delivery, enhanced 
stability in body fluids), but could limit some of the problems 
anticipated with biotechnologically engineered exosomes. 
Production of exosome mimetics is more easily scalable for 
use in preclinical or clinical settings. In addition, the assembly 
process of exosome mimetics is controllable and results in 
the formation of “clean”, well characterized drug delivery 
systems with high pharmaceutical acceptability. Moreover, 
the use of exosome mimetics allows us to study the effect of 
each component separately. However, the   components which 
are likely to be required for proper   functioning of exosome 
mimetics as drug delivery systems are not yet well defined in 
the literature. Therefore, this review aims to describe potential 
candidate components for the assembly of functional exosome 
mimetics.
Lipids
In 2009, an initiative was undertaken by Mathivanan and 
Simpson to create an online database of all studies on exo-
somal protein and nucleic acid content, named ExoCarta.72 
This allows scientists to catalogue exosome-specific pro-
teomic and genomic data and makes them available to other 
scientists in the field. ExoCarta has grown steadily since its 
development, and now contains 134 studies covering data of 
4049 proteins, 1639 mRNAs, and 764 miRNAs. Because it 
is increasingly understood that not only proteins and nucleic 
acids contribute to exosomal function, the feature to include 
data on exosomal lipids in the database has also recently 
been added.73 At this moment, only a handful of lipids has 
been registered in ExoCarta, including four prostaglandins 
(E2, F2, J2, and D2) and the conical lipid lysobisphospha-
tidic acid. Exosome-bound prostaglandins are involved in 
specific intracellular signaling pathways of the target cells74 
and thus do not appear to be essential for exosomal stability 
and delivery. 
Likewise, it is unlikely that lysobisphosphatidic acid 
plays a functional role in circulating exosomes. Exosomes 
derived from rat mast cells, human dendritic cells, and B cells 
have been found to contain only minor amounts of this lipid 
compared with their parent cells.75,76 Rather, the lipid may be 
involved in exosome biogenesis at the multivesicular body-
limiting membrane, where its abundant presence has been 
shown.77,78 It has been postulated that lysobisphosphatidic 
acid could contribute to vesicle budding at this membrane, 
without being incorporated in the newly formed exosomes 
itself.79 In addition, the lipid may be involved in fusion of 
endocytosed vesicles with lysobisphosphatidic acid-contain-
ing endosomal membranes. It has been demonstrated that 
some infectious particles, including vesicular stomatitis and 
dengue viruses, fuse with late endosomes through interac-
tions with lysobisphosphatidic acid, resulting in the release 
of their contents into the cytosol of the target cell.80–82 Thus, 
the activity of lysobisphosphatidic acid appears to be limited 
to intracellular fusion and budding processes.
The lipid bilayer of circulating exosomes appears to 
be mainly constituted of plasma membrane lipids, includ-
ing sphingomyelin, phosphatidylcholine, phosphatidyl-
ethanolamine, phosphatidylserine, ganglioside GM3, and 
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phosphatidylinositol.79 The ratios of these lipids vary among 
exosomes from different cell types. For instance, almost half 
of the lipids in exosomes derived from reticulocytes constitute 
phosphatidylcholine,83 whereas this lipid forms less than one 
third of total lipid content of mast cell-derived and dendritic 
cell-derived exosomes.75 In general, exosomes appear to be 
enriched in sphingomyelin, cholesterol, GM3, and phosphati-
dylserine compared with their parent cells.79 These lipids are 
not commonly used in liposomal drug delivery systems, but 
their incorporation can be advantageous. Sphingomyelin and 
cholesterol are thought to form hydrogen bonds, resulting in 
tight packing of sphingomyelin/cholesterol bilayers and low 
water permeability.84,85 In addition, they provide detergent 
resistance.86 Therefore, incorporation of these lipids in exo-
some mimetics may increase their rigidity and stability. Indeed, 
liposomes containing sphingomyelin/cholesterol have longer 
circulation times and show decreased insertion of plasma 
proteins into their membrane.87 Liposomes containing sphin-
gomyelin/cholesterol and loaded with vincristine have shown 
promising results in Phase II clinical trials, being tolerated at 
twice the dose of nonencapsulated vincristine in patients with 
aggressive non-Hodgkin lymphoma and showing a favorable 
side effect profile.88,89
GM3 may act as a stabilizer of the exosomal wall and may 
shield the vesicle from interactions with blood components. 
Gangliosides, sphingomyelin, and cholesterol were demon-
strated to act synergistically to decrease uptake of liposomes 
by the reticuloendothelial system both in vitro and in vivo.90,91 
However, Yokoyama et al demonstrated with DPPG/GM3 
liposomes that high molar concentrations (.15 mol%) of 
GM3 may induce membrane segregation and leakage from 
vesicles.92 Therefore, GM3 may be beneficial in exosome 
mimetics when used in low concentrations only.
The structural function of phosphatidylserine in biologi-
cal membranes is less well studied, but it is known to play a 
role as a signaling molecule in a large variety of biological 
processes. The biological role of phosphatidylserine may 
differ among vesicle populations and cellular sources. For 
instance, circulating erythrocytes gradually externalize phos-
phatidylserine during aging, providing an “eat-me” signal for 
the reticuloendothelial system.93 Allen et al showed that low 
concentrations of phosphatidylserine (.2 mol%) in the mem-
brane of erythrocyte-resembling liposomes were sufficient to 
induce clearance by this system dramatically, without affect-
ing membrane lipid organization.94 The “eat-me” signaling 
function of phosphatidylserine is nature’s way of clearing 
phosphatidylserine-exposing apoptotic cells by phagocytosis, 
reducing leakage of the cellular content to the extracellular 
matrix.95 The lipid may also serve as a docking station for 
factors of the coagulation cascade96 and has been suggested 
to play roles in other physiological processes, such as muscle 
formation and anti-inflammatory responses.97,98
Whilst these characteristics appear to be unfavorable 
for exosome mimetics, for which longer circulation times 
are often desired, incorporation of phosphatidylserine in 
exosome mimetics may be beneficial nonetheless. The 
natural conical shape of phosphatidylserine may aid in the 
assembly of the curved exosome mimetic membrane.99 In 
addition, conically shaped lipids facilitate fusion and fis-
sion of biological membranes.100–102 Phosphatidylserine 
could thus enhance fusion of exosome mimetics with target 
cell membranes and promote intracellular release of cargo. 
Indeed, it has been shown in a number of studies that inhibi-
tion of phosphatidylserine on microvesicle membranes by 
Annexin-V or Diannexin reduced fusion of microvesicles 
with the plasma membranes of their target cells,36,38,103,104 
indicating that phosphatidylserine is an important mediator 
of vesicle fusion. Moreover, it has been postulated that the 
negatively charged phosphatidylserine enhances the stability 
of cell membranes by electrostatic interactions with (cationic) 
skeletal proteins.105 This effect may be exploited in exo-
some mimetics loaded with cationic compounds, increasing 
the retention of encapsulated cargo. However, given that 
phosphatidylserine displayed on the outer layer of exosome 
mimetics may dramatically decrease their circulation time, 
incorporation of the lipid in exosome mimetics has to be 
carried out with caution.
Regardless of the exact lipid composition of extracellular 
vesicles, the lipid bilayer of exosomes appears to be adapted 
to their target environment. Extracellular pH may differ among 
target tissues, and rigidity of the vesicle needs to be maintained 
in these environments to assure optimal function. Parolini et al 
showed that exosomes released in an acidic microenviron-
ment contained higher concentrations of sphingomyelin and 
GM3 compared with exosomes from the same cellular origin 
but released in a buffered environment.106 These lipids were 
suggested to increase exosomal rigidity upon interaction with 
cholesterol.107 Moreover, they demonstrated enhanced fusion 
of acidic exosomes with target cells compared with exosomes 
secreted in buffered conditions. Given that the target cells 
(metastatic melanoma) are surrounded by an acidic extracel-
lular matrix under physiological conditions,106 this suggests 
that the lipid composition of exosomes may be tailored to their 
target microenvironment. The influence of extravesicular pH 
on exosome behavior was also demonstrated by Laulagnier 
et al, who showed that exosomal rigidity increased from 
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pH 5 to pH 7, a common transition during release of exosomes 
from acidic multivesicular bodies.75 The rigid bilayer at physi-
ological pH may enhance membrane fusion with target cells, 
but this was not investigated in this study.
Proteins
Although lipids are increasingly accepted to play important 
roles in exosomal function, exosome-associated proteins are 
indispensable. Such proteins can actively participate in regu-
latory processes and trigger cellular responses, but are also 
irrefutably involved in functional aspects of exosomes, such 
as assembly, (preventing) interaction with the extracellular 
matrix, and binding and fusion with target cells. For instance, 
it was demonstrated that cross-linking of proteins on exosomes 
by paraformaldehyde decreased exosomal fusion with parental 
cells by approximately 20%.106 Furthermore, when these exo-
somes were solubilized with octylglucoside and reconstructed 
by dialysis (removing membrane proteins), they showed a 
dramatically reduced ability to fuse with target cells compared 
with untreated exosomes. The fusion efficiency of the protein-
depleted exosomes was comparable with the fusion efficiency 
of large unilamellar vesicles with a lipid composition similar 
to that of the natural exosomes, confirming the importance of 
exosomal proteins in fusion events.106
According to a variety of proteomic studies (catalogued 
in ExoCarta), a number of proteins and protein families are 
abundantly detected in exosomes.30 Many of these, such as 
heat shock proteins, annexins, and proteins of the Rab family, 
are mainly involved in intracellular assembly and traffick-
ing of exosomes and may not be required further after the 
vesicles are secreted. Thus, the inclusion of such proteins 
in exosome mimetics would probably not be beneficial for 
drug delivery purposes. However, several other exosomal 
proteins or protein families may be exploited to enhance the 
delivery properties of exosome mimetics. It should be noted 
that incorporation of proteins in exosome mimetics is still a 
challenging task, especially when simultaneous incorporation 
of multiple components is desired. However, work in this 
area is progressing and has yielded promising results.108–112 
For instance, the functional reconstitution of a voltage-gated 
potassium channel and αbIIβ3 integrin in giant unilamellar 
vesicles was recently described.108,110 The potential advan-
tages of the incorporation of several exosomal proteins in 
exosome mimetics are discussed below.
Tetraspanins
Tetraspanins are a family of transmembrane proteins 
commonly detected in exosomes. Among them are CD9, 
CD63, CD81, and CD82, which are often used as exosome 
markers.30,113 Some tetraspanins are selectively enriched in 
exosomes compared with their parent cells. An example is 
CD9, which was found to be more than 10-fold enriched in 
dendritic cell-derived exosomes.114 CD37, CD63, CD81, 
and CD82 were abundantly detected in exosomes derived 
from B lymphocytes.115 Atay et al demonstrated that CD81 
was selectively enriched in exosomes from trophoblast 
cells, but could not detect CD63 (considered to be a canoni-
cal exosomal protein) in either parent cells or exosomes.116 
  Tetraspanin enrichment patterns in exosomes thus vary 
among parent cells.
Tetraspanins have been relatively understudied due to 
their limited ligand-receptor interaction and their small size, 
which in some cases may prevent biochemical or immuno-
logical detection.117 However, their functions as mediators 
of fusion, cell migration, cell-cell adhesion, and signaling 
events designate them as interesting targets in the field of drug 
discovery.118 Moreover, their functions in exosomes (albeit 
largely unknown) may be exploited to enhance the properties 
of exosome mimetics as drug delivery systems.
The tetraspanin, CD9, has been shown to mediate fusion 
processes in a variety of cell types. Miyado et al demonstrated 
that egg cells from CD9 knockout mice (CD9-/-) failed to fuse 
with sperm cells from wild-type males, although binding 
between the two cell types was unaltered. Normal fusion 
events were observed between sperm cells and CD+/+ eggs, 
suggestive of an involvement of CD9 in the fusion process. 
Moreover, when CD9 on eggs was blocked with anti-CD9 
antibodies, fusion was significantly inhibited.119 A role of 
CD9 in fusion processes was also evidenced by Tachibana 
and Hemler, who showed that blocking CD9 and CD81 on 
myoblast cells inhibited cell fusion to syncytia, and upregula-
tion of the two tetraspanins resulted in enhanced cell fusion.120 
It has been suggested that tetraspanin-mediated cell fusion is 
exploited by various viruses, allowing them to spread while 
avoiding exposure to the humoral immune system.121,122 
However, the fusogenic properties of CD9 and CD81 were 
contradicted by studies of the fusion behavior of mononuclear 
phagocytes. Incubation of these cells with antibodies 
against CD9 and CD81 resulted in enhanced formation of 
multinucleated giant cells, and CD9-/- and CD81-/- alveolar 
macrophages formed 3–4-fold more multinucleated giant 
cells than wild-type cells.123 These results were supported by 
Parthasarathy et al, who additionally showed that, in contrast 
with CD9 and CD81, CD63 in fact promoted monocyte 
fusion.124 Thus, the fusogenic properties of tetraspanins 
appear to be dependent on cell type.
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Interestingly, the tetraspanins which are often found to be 
enriched in exosomes (CD9, CD63, CD81, and CD82)30,113 
have been shown to be involved in the migration of dendritic 
cells. In a chemotaxis assay, antibodies against the single 
tetraspanins increased migration of these cells by 50%–70%, 
while 100% increased migration was observed when these 
antibodies were combined.125 The increase in migration 
was attributed to decreased binding of the cells to integrins 
expressed in the extracellular matrix. These results suggest 
that tetraspanins in exosomal membranes may facilitate their 
binding to target cells.
Although fusogenic and matrix-binding properties 
of tetraspanins in cell membranes have been described, 
not much is known about the functions of tetraspanins in 
exosomes. However, tetraspanins, Tspan8, CD49d, and 
CD106, appeared to be involved in binding and uptake of 
pancreatic adenocarcinoma-derived exosomes by fibroblasts 
and endothelial cells.126 It has also been suggested that CD9 
is involved in fusion of exosomes with their target cells,52 
indicating that tetraspanins may have similar functions in 
exosomes and cell membranes.
It is important to consider that tetraspanins probably exert 
most of their functions in unison with other membrane pro-
teins. In cell membranes, tetraspanins are laterally organized 
in tetraspanin-enriched microdomains, which are resistant 
to mild detergent conditions. Tetraspanin-enriched micro-
domains generally contain integrins, signaling molecules, 
and other tetraspanins, and are involved in a variety of cell 
fusion, cell adhesion strengthening, and signaling events, 
as excellently reviewed previously.117,118,127,128 The effects 
of single tetraspanins, particularly in extracellular vesicles, 
are still poorly understood. Incorporation of tetraspanins 
in exosome mimetics may therefore not only enhance exo-
some mimetic functioning (ie, binding and uptake in target 
cells), but may also provide important clues on tetraspanin 
functioning in exosomes.
Adhesion molecules
According to the ExoCarta database, integrins are among the 
most abundant proteins detected in exosomes derived from 
cancer and immune cells.129 Integrins are membrane-spanning 
proteins which exist as heterodimers of α and β subunits. 
A total of 24 different heterodimers have been identified in 
vertebrates, of which β1, β2, and αv integrins comprise the 
largest group. They function primarily as adhesion molecules 
and establish cell binding to the extracellular matrix, although 
other functions have been described.130,131 In exosomes, inte-
grins are most likely involved in addressing the vesicles to 
their target cells.31 Therefore, incorporation of integrins in 
exosome mimetics may potentiate their interactions with the 
extracellular matrix, increasing their delivery potential.
Given that integrins are abundantly detected in a range 
of exosomal preparations (especially those derived from 
cancer cells),132,133 it is surprising that only a limited num-
ber of studies have addressed the functional role of these 
adhesion molecules in exosomes. In seminal work by Rieu 
et al, it was shown that integrin α4β1 is present on the sur-
face of young reticulocytes and its surface levels decrease 
during maturation.134 The adhesion molecules of mature 
reticulocytes were detected in the exosomal fraction, sug-
gesting that the cells use exosomes to dispose of integrins. 
Functional examination of the exosomes showed that α4β1 
integrin mediated binding of the exosomes to fibronectin. 
This binding was dependent on divalent cations (Mg2+, Mn2+) 
and was significantly inhibited by the α4β1-binding domain 
of fibronectin and anti-α4 antibodies. In similar work, it was 
found that exosomes from fibroblasts and epithelial cells 
contained β1 integrins and that exosomes from human B 
cells expressed both β1 and β2 integrins.135 B cell-derived 
exosomes bound collagen I and fibronectin in a cation-
dependent manner, and binding was inhibited by antibodies 
against α4 and β1 integrins. Moreover, it was shown that 
these exosomes strongly adhered to tumor necrosis factor 
alpha-stimulated fibroblasts through an integrin-intercellular 
adhesion molecule (ICAM-1) interaction. Integrin β1 and 
CD9 were also detected on the surface of retroviral particles, 
and it was suggested that these contribute to adhesion of 
viruses to host cells.136 Taken together, these results suggest 
that exosomal integrins play a crucial role in establishing 
exosomal adhesion to the extracellular matrix. Given that 
binding to target cells is the first step in intracellular drug 
delivery, incorporation of integrins into exosome mimetics 
may thus greatly enhance their drug delivery potential. This 
strategy has not been implemented in drug delivery systems 
yet, but integrin-ligand interactions have been successfully 
exploited. For instance, the fibronectin-derived RGD peptide 
is commonly used to target drug delivery systems to αvβ3 
integrin, which is overexpressed in tumor vasculature.137 
Integrin incorporation in exosome mimetics may work in 
a similar fashion to deliver therapeutics to specific tissues. 
It has been shown that integrin αIIbβ3 can be incorporated 
into liposomal membranes without losing its ability to bind 
to its ligands.109,138 However, the affinity of this integrin for 
its ligand, cyclo(RGDfV), was higher in cell membranes 
than in liposomes,139 suggesting that other endogenous 
membrane molecules (eg, tetraspanins, lipids) contribute 
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to   integrin-mediated adhesion. Indeed, such a   synergistic 
effect was demonstrated in a study by Zheng et al,111 who 
incorporated integrin α5β1 into phosphatidylcholine/cho-
lesterol liposomes containing increasing concentrations of 
ganglioside GM3 (0–10 nmol/55 µg phosphatidylcholine). 
The binding of the liposomes to fibronectin-coated plates 
differed significantly among varying concentrations of GM3, 
and was optimal at GM3 concentrations of 0.2–0.4 nmol 
(0.22–0.44 µg)/55 µg phosphatidylcholine. In addition, mam-
mary carcinoma cells mutated to contain high concentrations 
of GM3 bound better to these plates than their parent cells, 
further evidencing the synergistic effect of other membrane 
components to integrin function.111 Given that the membranes 
of exosome mimetics resemble those of endogenous exo-
somes, integrin incorporation may be a powerful strategy to 
enhance the adhesive properties of exosome mimetics.
In addition to integrins, other adhesion molecules which 
may be potentially exploited in exosome mimetics have been 
identified in exosomes. Comprehensive proteomic studies 
have identified thrombospondin 1 in exosomes in the urine, 
plasma, and saliva of healthy volunteers.140–143 In addition, 
thrombospondin 1 and thrombospondin 2 were detected in 
exosomes from patients diagnosed with various types of 
cancer, and in exosomes derived from a colon cancer cell 
line.144,145 Thrombospondin 1 contains a variety of adhesive 
domains, including an RGD sequence that binds αvβ3 inte-
grins.146 Nucera et al demonstrated that the protein plays 
an important role in cancer metastasis.147 They showed that 
knockdown of the thrombospondin 1 gene in papillary thyroid 
carcinoma cells decreased their adhesion and migration in 
vitro and in vivo, and that treatment with a thrombospondin 
1 inhibitor decreased metastasis and tumor growth in an 
orthotopic mouse model. In an attempt to use the adhesive 
properties of thrombospondins for targeted drug delivery, 
Rivera-Fillat et al developed aspartimide analogs of throm-
bospondin 1 and 2 and conjugated them to liposomes loaded 
with doxorubicin.148 Both peptides adhered to endothelial 
cells and colon carcinoma cells in vitro. In addition, it was 
demonstrated that the thrombospondin 1 analog enhanced 
the antitumor effect of doxorubicin-loaded liposomes in 
mice bearing a human colon carcinoma; tumor growth was 
inhibited and mouse survival was prolonged compared with 
the nontargeted doxorubicin liposomes. This effect was most 
likely due to enhanced delivery of doxorubicin to target 
cells, given that targeted liposomes without doxorubicin 
did not exert antitumoral activity. In addition to conferring 
adhesion properties, thrombospondins also serve as signal-
ing molecules with antiangiogenic and antitumoral effects. 
Therefore, they may have therapeutic potential on their own, 
and have been reviewed elsewhere.149,150 Thrombospondins 
may thus be valuable tools in tumor-targeted exosome mimet-
ics; they may promote adhesion to target cells and induce 
antiangiogenic signaling pathways.
A third interesting class of adhesion molecules found 
associated with exosomes is the family of ICAMs. ICAM-1 
and ICAM-3 have been detected in immune cell-derived 
exosomes41,115,151–153 and may function as important mediators 
in immune responses. ICAM-1 is a ligand for integrin αLβ2 
(LFA-1) and Mac-1, and promotes leukocyte adhesion,154 
while ICAM-3 binds DC-SIGN on dendritic cells.155 Their 
functions in exosomes are still under investigation, although 
some interesting results have been published. Segura et al 
showed that exosomes from mature dendritic cells contained 
markedly more ICAM-1 compared with those from immature 
dendritic cells.156 Mature exosomes induced T cell activation 
and proliferation in vitro, and enhanced T cell activation 
and skin graft rejection in vivo compared with immature 
exosomes. The authors showed that ICAM-1 expression was 
an important contributor to this process, and suggested that 
ICAM-1 mediates exosome adhesion to target antigen-pre-
senting cells, thereby inducing the immune response.156 In a 
follow-up study, the group showed that ICAM-1-exposing 
exosomes induced significantly stronger T cell responses 
than ICAM-1-/- exosomes in vitro and in vivo, and that this 
effect was due to loss of exosome-cell adhesion mediated 
by ICAM-1 and LFA-1.157 These results demonstrate the 
importance of ICAM-1 in the adhesion of exosomes to LFA-
1-expressing immune cells. When targeting the immune 
system (eg, in vaccine preparations), the incorporation of 
ICAM-1 into exosome mimetics may be considered.
Other membrane proteins
Apart from tetraspanins and adhesion molecules, other 
proteins which also have the potential to enhance the drug 
delivery properties of exosome mimetics have been identi-
fied in exosomes. Two of these, CD55 and CD59, have been 
found in exosomes derived from various sources, including 
B cells, dendritic cells, colorectal cancer cells, saliva, and 
bronchial epithelial cells.66,141,145,153,158,159 Both factors protect 
cells from complement-mediated lysis; CD55 accelerates the 
decay of autologous complement factors,160 whereas CD59 
prevents activation of the membrane attack complex by 
inhibition of C9 incorporation in C5b-9.161 In an interesting 
study by Clayton et al, it was demonstrated that inhibition of 
exosomal CD55 resulted in increased membrane disposition 
of C3b and exosome lysis.66 Blockade of CD59 also enhanced 
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complement-mediated exosome lysis, and inhibition of both 
CD55 and CD59 increased lysis even further. These proteins 
thus appear to protect exosomes from complement-mediated 
lysis. Given that liposomes are prone to lysis mediated by 
complement factors,162,163 CD55 and CD59 may be used 
to improve the stability and circulation time of exosome 
mimetics.
Another exosomal protein with possible therapeutic 
applications is lactadherin (also known as EGF-factor VIII 
or MFG-E8).114 This protein is commonly found in exo-
somes derived from immune cells114,164,165 and fibroblasts.166 
  Lactadherin consists of two EGF-like domains and two 
lectin type C domains (C1 and C2) with high homology to 
coagulation factors V and VIII.167 The EGF-like domains 
mediate binding to integrins αvβ3 and αvβ5 via an RGD motif, 
while the C2 domain promotes binding to phosphatidylser-
ine in biological membranes.168 Thus, it acts as a scaffold 
protein between the surface of phosphatidylserine-exposing 
  apoptotic cells or exosomes and target cells. It has been 
reported that lactadherin promotes adhesion and uptake of 
exosomes by dendritic cells,169 but also interactions with other 
phagocytotic cells expressing integrins αvβ3/5, such as mac-
rophages and endothelial cells, are likely.114 To demonstrate 
that angiogenic endothelial cells are capable of phagocytosis, 
Fens et al prepared phosphatidylserine-exposing liposomes 
and opsonized them with lactadherin.170 Marked uptake of 
the opsonized liposomes in human umbilical vein endothelial 
cells was observed, whereas uptake was several-fold lower 
in the absence of lactadherin. Moreover, membrane vesicles 
containing egg phosphatidyl glycerol, which is a negatively 
charged phospholipid that lacks a lactadherin binding site, 
were barely taken up by human umbilical vein endothelial 
cells in the presence of the opsonin. These results show that 
lactadherin may be used to target exosome mimetics to spe-
cific integrin-expressing cells, such as angiogenic endothelial 
cells and dendritic cells.
Furthermore, it has been shown that fusion proteins 
containing the lactadherin C1C2 domain can be exploited 
to induce immune responses to tumor antigens.56–58 In such 
strategies, the phosphatidylserine-binding domain of the 
opsonin is used to coat exosomes and exploit the excellent 
delivery potential of these vesicles to deliver the antigen to 
antigen-presenting cells, resulting in immune responses. 
These studies illustrate the versatility of the lactadherin pro-
tein and its application in exosome mimetic-mediated drug 
delivery. An advantage of lactadherin is that it does not need 
to be incorporated in the membrane of exosome mimetics. 
Rather, it is possible to produce the protein recombinantly171 
and attach it to phosphatidylserine-exposing exosome   mimetics 
after vesicle formation. Additionally, fusion proteins of 
lactadherin and functional domains of other proteins can 
be engineered, conferring unique properties to exosome 
mimetics coated with these constructs. For instance, by 
fusing the C1C2 domain of lactadherin to targeting ligands, 
exosome mimetics may be targeted to specific organs and 
cell types. An additional advantage of lactadherin coating 
of phosphatidylserine-exposing exosome mimetics is that 
recognition of the lipid by phosphatidylserine receptors may 
be blocked. This way, the “eat-me” signaling function of 
phosphatidylserine would be inhibited, resulting in prolonged 
circulation time of the vesicles.
Decoration of exosome mimetics with specific proteins 
may also be achieved by the use of exosomal membrane 
anchors. In contrast with lactadherin, which is coated on the 
surface of exosome mimetics, such anchors may be plugged 
into the exosome mimetic membrane during exosome mimetic 
assembly and provide a stable scaffold for fused proteins. An 
example is Lamp2b, which was used by Alvarez-Erviti et al 
to anchor the neuron-specific RVG peptide to the exosomal 
membrane.53 Although this study exploited the endogenous 
exosomal pathway to incorporate the anchor into exosomes, 
it may be possible to reconstitute the protein into an artificial 
membrane (ie, exosome mimetic membrane). Thus, linkage 
of exosome mimetics to proteins which are not naturally 
expressed in exosomes may be achieved, circumventing 
possible expression issues in biotechnologically engineered 
exosomes. Such issues were clearly demonstrated by Shen 
et al, who attempted to target a highly oligomeric cytoplasmic 
protein (TyA-GFP) to secreted vesicles by fusing the protein 
to a variety of exosomal membrane proteins, including CD4, 
CD38, CD43, CD69, and CD83.172 After transfection of 
Jurkat T cells with expression vectors encoding the fusion 
proteins, only CD43-TyA-GFP could be weakly detected in 
the secreted vesicles. The authors suggested that endoplasmic 
reticulum-associated degradation could be responsible for 
the undetectable exosomal expression of some of the other 
constructs. A small number of constructs was degraded nor 
secreted, but was found to be retained in the endoplasmic 
reticulum instead. In this regard, the synthetic construction 
of exosome mimetics can offer a solution. A promising novel 
technique to incorporate membrane proteins into liposomes 
is the cell-free expression of such proteins in the presence 
of liposomes.173–175 Using this technique, integral membrane 
proteins are inserted into the liposomal membrane during 
their expression, resulting in functional and stable protein 
incorporation. Successful cell-free expression in liposomes 
submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
1534
Kooijmans et alInternational Journal of Nanomedicine 2012:7
has been demonstrated for a number of membrane proteins, 
such as membrane channel proteins.175–177
Therapeutic cargo
Exosome mimetics provide an opportunity to deliver thera-
peutic cargo directly into the cytoplasm of target cells. It is 
possible to load exosome mimetics with synthetic drugs, as 
is commonly done in other liposomal formulations,178,179 but 
the unique exosome-resembling characteristics of exosome 
mimetics allow them to excel in the delivery of therapeutic 
proteins and nucleic acids. An interesting class of molecules 
which could benefit from exosome mimetic-mediated 
delivery are miRNAs. These short noncoding endogenous 
RNA molecules recruit cellular proteins and bind to target 
mRNA sequences via Watson-Crick base-pairing, resulting in 
cleavage or translation repression of the target strand (RNA 
interference). This way, they regulate protein expression and 
cellular functioning.180 Given the discovery that miRNAs are 
not only involved in the regulation of cellular processes in the 
miRNA-producing cell, but that they also regulate processes 
in other cells by exosomal transfer,41 the therapeutic applica-
tions of miRNAs have gained increasing attention.
Intracellular levels of miRNAs have been extensively 
mapped in a number of diseases. Among the most studied 
diseases in this regard is cancer, in which specific miRNAs 
are often overexpressed or underexpressed compared with 
healthy cells.181 Low levels of cancer-associated miRNAs 
can be compensated by miRNA-based therapeutics (so-called 
miRNA restoration or replacement), resulting in improve-
ment of the disease outcomes. Successful restoration of 
miRNA to treat various types of cancer has been described 
in a number of recent studies and was reviewed recently by 
Henry et al.182 For instance, in 2009, Kota et al showed that 
the expression of the miRNA, miR-26a, in liver tumors was 
markedly decreased compared with healthy liver tissue.183 
To test whether restoration of miR-26a could have antitu-
morigenic effects, an adeno-associated virus vector packed 
with miR-26a was intravenously administered to liver tumor-
bearing mice. Three weeks after treatment, disease progres-
sion was dramatically decreased, cancer cell proliferation was 
inhibited, and tumor cell-specific apoptosis was increased 
compared with mice treated with empty vectors. The 
therapeutic effect of miRNA restoration was also shown for 
miR-34a, which was found to be underexpressed in prostate 
cancer cells.184 Upon repetitive intravenous administration of 
miR-34a complexed with a lipid-based delivery agent to mice 
with prostate cancer xenografts, tumor growth and metastasis 
were inhibited and mouse survival was prolonged. These 
effects were likely due to miR-  34a-mediated downregulation 
of the adhesion molecule CD44 in tumor cells.184
While some miRNAs appear to be downregulated in 
various disease states, other miRNAs have been shown 
to be overexpressed. This phenomenon has supported the 
emergence of anti-miRNA-based therapeutics.185 These are 
antisense oligonucleotides with sequences complementary 
to those of the targeted miRNA, which disrupt miRNA 
biogenesis and functioning at multiple fronts (eg, miRNA 
processing and interactions with the target mRNA).186 Several 
interesting studies have effectively employed anti-miRNA 
strategies to induce cancer cell death and inhibit disease 
progression.187–191
These exciting results illustrate the potential of   miRNAs 
and anti-miRNAs as a novel class of endogenous   therapeutics. 
However, the intracellular delivery of (anti-)miRNAs is 
generally poor, and multiple (intratumoral) injections are 
often required for an effect.192,193 Given that exosomes are 
natural carriers for miRNAs, exosome mimetics would be 
excellent delivery systems for such molecules. Because their 
membrane resembles that of natural exosomes, the stability of 
encapsulated miRNAs could be increased. Furthermore, exo-
some mimetics may allow for nontoxic and nonimmunogenic 
delivery of their cargo to target cells, strongly potentiating 
the effects of (anti-)miRNAs.
Although miRNAs are promising therapeutic targets, it is 
important to note that they do not require full (100%) binding 
to their target mRNA sequences for inhibiting effects.194 This 
allows them to act synergistically on various targets within 
signaling pathways, but also increases their chance for off-
target effects. These can be minimized by extensive charac-
terization of possible target sequences and optimization of the 
administered miRNA doses. Alternatively, siRNA, which is 
known for its excellent sequence specificity,195 may be used 
to silence the expression of specific target genes. Similar to 
miRNA, the properties of siRNA (eg, their anionic charge, 
size, and rapid clearance) call for packaging in adequate 
delivery systems. Given that biotechnologically engineered 
exosomes have previously been successfully applied for 
delivery of siRNA,53 exosome mimetics hold great potential 
for siRNA-delivery.
Conclusion and perspectives
The safe and effective delivery of drug molecules to their 
target site is a field which has increasingly gained attention 
in drug design and development. In recent decades, the focus 
has shifted from synthetic drug compounds to the delivery of 
biological drugs (ie, proteins and nucleic acids), which are 
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very prone to immune effects and degradation. In this regard, 
exosome mimetics are promising candidate delivery vehicles, 
given that they mimic nature’s delivery vehicles of biologi-
cals, but are not as complex as their biological counterparts. 
These characteristics may allow them to deliver biologicals 
in an effective and safe manner, with high pharmaceutical 
acceptability due to their well characterized components. 
However, before the full potential of exosome mimetics 
can be exploited, a number of challenges still need to be 
  overcome. The assembly of liposomes with varying sizes 
and lipid compositions is commonly performed and well 
understood, but the incorporation of functional proteins and 
nucleic acids with reasonable efficiency is a field on its own. 
Membrane proteins have been successfully incorporated in 
liposomes without losing their functionality,108–112 but the 
incorporation of multiple proteins is a time-consuming and 
complicated process. Their membrane localization may 
require a specific lipid composition and chaperone proteins. 
Moreover, the (recombinant) production of membrane pro-
teins is a challenging task due to their high hydrophobicity 
and cytotoxicity, tendency to form aggregates, and low 
expression levels. The use of promising cell-free expression 
systems may aid to overcome these production issues.173–175
For assembly of functional exosome mimetics, it is also 
important to take into account the structural and biological 
functions of the lipids to be incorporated. Lipids come in 
various sizes and shapes, which influence the behavior of 
the liposome in biological environments (eg, fusion and 
stability). In this regard, it may be wise to borrow a leaf from 
nature’s book and mimic the lipid composition of exosomes 
in the intended target environment for optimal functionality. 
Increasingly powerful analytical methods in the field of lipi-
domics may aid in elucidating both function and composition 
of lipids in natural exosomes. These may provide valuable 
clues for drug delivery with exosome mimetics.
An additional challenge governing the assembly of func-
tional exosome mimetics is the loading of therapeutic cargo. 
Although work is progressing in this area, high-efficiency 
loading of siRNA (and likewise miRNA) in lipid vesicles 
is still rarely achieved.196,197 Given that exosomes are loaded 
with multiple components that probably contribute to the 
outstanding delivery capacities of these vesicles, efficient 
loading of a combination of nucleic acids and proteins in 
exosome mimetics merits investigation. Furthermore, it 
is important to note that crucial components of exosomes 
are still largely unknown, and probably differ among exo-
somes with varying functions and target cells. The rapidly 
expanding field of exosomics allows us to increase our 
  understanding of the composition and function of these 
intriguing vesicles, but is still in its infancy. Extensive 
proteomic studies have identified more than 4000 proteins 
and more than 1500 miRNAs in exosomes from various 
sources, but integrative studies are required to elucidate 
the biological functions of these components. The answer 
to “What makes natural exosomes such effective delivery 
vehicles?”, is the first step towards the design and assembly 
of functional exosome mimetics.
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